Skip to main content

Advertisement

SpringerLink
Log in

Association of interleukin-10 gene variation with breast cancer prognosis

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Genetic polymorphisms are responsible for inter-individual variation and diversity and have been recently considered as the main genetic elements involved in the development and progression of cancer. We examined associations between common germline genetic variants in 7 genes involved in folate metabolism, cell proliferation and apoptosis, prostaglandin synthesis, detoxification of compounds and inflammation, and disease-free survival among women diagnosed with invasive breast cancer. DNA from up to 432 women was genotyped for 8 polymorphisms. The genotypes of each polymorphism were tested for association with disease-free survival using univariate and multivariate Cox regression analysis. The model was adjusted for known breast cancer prognostic factors. The rare allele of the IL-10 592C>A polymorphism was significantly associated with reduced disease-free survival (P = 0.018, risk ratio of recurrence (RR) = 1.45, 95% confidence interval (CI) = 1.06–1.98), which was not attenuated after adjusting for age at diagnosis, tumor size, lymph node status, clinical stage, histological grade, estrogen receptor status, progesterone receptor status, and treatment modalities (P = 0.019, RR = 1.48, 95% CI = 1.066–2.044). No association was found between MTHFR 677C>T, TGFB1 29T>C, FASLG 844C>T, FAS 1377G>A, FAS 670A>G, PTGS2 8473T>C and SULT1A1 638G>A polymorphisms and disease-free survival. Our data suggest that the rare allele of IL-10 592C>A may be a potential prognostic marker in breast cancer for disease-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rannala B (2001) Finding genes influencing susceptibility to complex diseases in the post-genome era. Am J Pharmacogenomics 1(3):203–221. doi:10.2165/00129785-200101030-00005

    Article  CAS  PubMed  Google Scholar 

  2. Weigelt B, Peterse JL, van‘t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5:591–602. doi:10.1038/nrc1670

    Article  CAS  PubMed  Google Scholar 

  3. Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics. CA Cancer J Clin 55:74–108. doi:10.3322/canjclin.55.2.74

    Article  Google Scholar 

  4. Hunter K (2005) The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination. Cell Cycle 4(12):1719–1721

    CAS  PubMed  Google Scholar 

  5. Hsieh SM, Lintell NA, Hunter KW (2007) Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer. Breast Dis 26:157–162

    CAS  Google Scholar 

  6. Hunter K (2006) Breast host genetics influence tumour metastasis. Nat Rev Cancer 6(2):141–146. doi:10.1038/nrc1803

    Article  CAS  PubMed  Google Scholar 

  7. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672–4678. doi:10.1200/JCO.2008.16.1612

    Article  CAS  PubMed  Google Scholar 

  8. Lenz HJ (2004) The use and development of germline polymorphisms in clinical oncology. J Clin Oncol 22(13):2519–2521. doi:10.1200/JCO.2004.04.900

    Article  CAS  PubMed  Google Scholar 

  9. Hayes DF, Ethier S, Mippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100:237–238. doi:10.1007/s10549-006-9253-5

    Article  PubMed  Google Scholar 

  10. McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. doi:10.1007/s10549-006-9242-8

    Article  PubMed  Google Scholar 

  11. Langsenlehner U, Krippl P, Renner W et al (2003) The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 81(2):169–172. doi:10.1023/A:1025752420309

    Article  CAS  PubMed  Google Scholar 

  12. Langsenlehner U, Krippl P, Renner W et al (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90(2):113–115. doi:10.1007/s10549-004-3607-7

    Article  CAS  PubMed  Google Scholar 

  13. Krippl P, Langsenlehner U, Renner W et al (2004) Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96(19):1478–1479

    Article  PubMed  Google Scholar 

  14. Krippl P, Langsenlehner U, Renner W et al (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201(2):181–184. doi:10.1016/S0304-3835(03)00468-3

    Article  CAS  PubMed  Google Scholar 

  15. Langsenlehner U, Krippl P, Renner W et al (2004) Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast Cancer Res Treat 87(1):19–22. doi:10.1023/B:BREA.0000041574.90735.ea

    Article  CAS  PubMed  Google Scholar 

  16. Langsenlehner U, Yazdani-Biuki B, Eder T et al (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12(4):1392–1394. doi:10.1158/1078-0432.CCR-05-2055

    Article  CAS  PubMed  Google Scholar 

  17. Gerger A, Langsenlehner U, Renner W et al (2007) A multigenetic approach to predict breast cancer risk. Breast Cancer Res Treat 104(2):159–164. doi:10.1007/s10549-006-9408-4

    Article  CAS  PubMed  Google Scholar 

  18. Mocellin S, Marincola F, Rossi CR et al (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76. doi:10.1016/j.cytogfr.2003.11.001

    Article  CAS  PubMed  Google Scholar 

  19. Fiorentino DF, Zlotnik A, Mosmann TR et al (1991) IL10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822

    CAS  PubMed  Google Scholar 

  20. Turner DM, Williams DM, Sankaran D et al (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8

    CAS  PubMed  Google Scholar 

  21. Crawley E, Kay R, Sillibourne J et al (1999) Polymorphic haplotypes of the interleukin-10 5’ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42:1101–1108. doi:10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y

    Article  CAS  PubMed  Google Scholar 

  22. Lin MT, Storer B, Martin PJ et al (2003) Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349:2201–2210. doi:10.1056/NEJMoa022060

    Article  CAS  PubMed  Google Scholar 

  23. Holler E, Roncarolo MG, Hintermeier-Knabe R et al (2000) Prognostic significance of increased IL10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 25:237–241. doi:10.1038/sj.bmt.1702126

    Article  CAS  PubMed  Google Scholar 

  24. Balasubramanian SP, Azmy IA, Higham SE et al (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188. doi:10.1186/1471-2407-6-188

    Article  CAS  PubMed  Google Scholar 

  25. Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5(2):143–149. doi:10.1007/s10689-005-0072-3

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Internal Medicine, Medical University Graz, Austria, Auenbruggerplatz 15, 8036, Graz, Austria

    Armin Gerger, Günter Hofmann, Gudrun Knechtel, Joanna Szkandera & Hellmut Samonigg

  2. Clinical Institute of Medical and Laboratory Diagnostics, Medical University Graz, Austria, Auenbruggerplatz 15, 8036, Graz, Austria

    Wilfried Renner

  3. Clinic of Therapeutic Radiology and Oncology, Medical University Graz, Austria, Auenbruggerplatz 15, 8036, Graz, Austria

    Tanja Langsenlehner

  4. Department of Internal Medicine, Regional Hospital of Fuerstenfeld, Krankenhausgasse 1, 8280, Fuerstenfeld, Austria

    Peter Krippl

  5. Internal Outpatient Department, Steiermaerkische Gebietskrankenkasse, Josef-Pongratz-Platz 1, 8011, Graz, Austria

    Uwe Langsenlehner

Authors
  1. Armin Gerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wilfried Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanja Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Günter Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gudrun Knechtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joanna Szkandera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hellmut Samonigg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter Krippl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Uwe Langsenlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Armin Gerger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerger, A., Renner, W., Langsenlehner, T. et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119, 701–705 (2010). https://doi.org/10.1007/s10549-009-0417-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0417-y

Keywords

Search

Navigation